Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

  • Awaiting development
  • GID-TA11487
  • Expected publication date: TBC

NIHRIO BN: 34113-Tucatinib-Trastuzumab-Pertuzumab-for-Breast-Cancer-V1.0-NOV2023-NON-CONF.pdf (nihr.ac.uk)